Calliditas Therapeutics AB (publ)’s (CALT) “Neutral” Rating Reaffirmed at Citigroup

Citigroup reaffirmed their neutral rating on shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) in a report issued on Friday, Benzinga reports. The firm currently has a $39.00 price objective on the stock.

Several other research analysts have also recently weighed in on the company. Jefferies Financial Group reissued a hold rating and issued a $39.00 price objective (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. Stifel Nicolaus reissued a hold rating and issued a $40.00 price objective (down previously from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. HC Wainwright reissued a neutral rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. Finally, Lifesci Capital cut Calliditas Therapeutics AB (publ) from a strong-buy rating to a hold rating in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $35.00.

Get Our Latest Stock Report on CALT

Calliditas Therapeutics AB (publ) Trading Up 3.9 %

Shares of Calliditas Therapeutics AB (publ) stock opened at $39.99 on Friday. The stock has a fifty day simple moving average of $21.99 and a 200 day simple moving average of $21.81. Calliditas Therapeutics AB has a 12-month low of $15.25 and a 12-month high of $40.00. The company has a market capitalization of $1.19 billion, a P/E ratio of -21.62 and a beta of 1.50. The company has a current ratio of 2.69, a quick ratio of 2.62 and a debt-to-equity ratio of 8.46.

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The company had revenue of $28.43 million for the quarter, compared to the consensus estimate of $35.78 million. On average, sell-side analysts anticipate that Calliditas Therapeutics AB will post -0.41 earnings per share for the current fiscal year.

Institutional Trading of Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is owned by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

(Get Free Report)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

Featured Stories

Analyst Recommendations for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.